 Context Therapeutics NASDAQ:CNTX Inc, a clinical-stage biopharma company focused on advancing medicines for cancers in women, posted results for the third quarter that revealed ample cash on hand, giving the company scope to advance its pipeline programs. As of September 30, 2022, the Philadelphia-based womens oncology company developing treatments for breast and gynecological cancers, had cash, equivalents, and restricted cash which totaled 39 million. 